A common vegetable has unexpectedly provided Australian scientists with a new lead in the quest for better treatments for Friedreich ataxia. A naturally occurring compound in broccoli might help correct one of the fundamental issues behind this rare and serious neurological disorder. The compound is called sulforaphane.
Researchers from Swinburne University of Technology report that sulforaphane can increase levels of an essential protein that is abnormally low in people with Friedreich ataxia. It may also offer protective benefits to nerve cells, shielding them from damage. The findings, published in Antioxidants & Redox Signaling, are still early in development, but scientists hope this research could eventually result in an affordable, accessible treatment option.
Friedreich ataxia is a hereditary disease caused by a defective gene. It develops when a child inherits altered copies of this gene from both parents, who might carry the genetic change without showing symptoms themselves. This mutation hampers the production of a protein called frataxin, which is vital for the tiny energy-producing structures within cells. A deficiency in frataxin can disrupt normal cellular function over time, leading to nerve cell damage and death.
The disease predominantly impacts the spinal cord and the nerves controlling movement, resulting in issues with balance, coordination, and muscle control. Early signs often include difficulty walking or frequent stumbling. As it worsens, some individuals eventually require wheelchairs and may encounter problems with speech, swallowing, and other daily activities.
Friedreich ataxia isn’t limited to the nervous system; it can also affect the heart and other organs, with these complications significantly impacting overall health and lifespan. It is believed that only around 200 Australians are living with the condition. Because of its rarity, awareness remains limited, and securing funding for the extensive research needed to develop treatments can be challenging.
Associate Professor Faith Kwa and her colleagues at Swinburne have explored whether sulforaphane, which naturally exists in broccoli and related vegetables, might provide a new therapeutic approach. The interest in this compound has grown due to its ability to bolster the body’s defenses against cellular damage.
In their recent experiments, sulforaphane increased frataxin levels, addressing a core aspect of Friedreich ataxia rather than just a consequence of the disease. It also appeared to protect vulnerable nerve cells, influencing processes related to inflammation and cellular stress. These effects suggest that sulforaphane may influence multiple disease pathways simultaneously.
Kwa describes Friedreich ataxia as a devastating condition that gradually robs children of their ability to walk, speak, and play. Despite many children being affected, options for treatment remain limited. The researchers highlight sulforaphane’s practical advantages—it has already been tested for safety in both children and adults, and pure, active forms are commercially accessible.
However, this does not mean sulforaphane is an approved treatment yet. The next critical step is to conduct clinical trials to confirm whether these biological effects translate into real health benefits for patients. These studies will need to determine appropriate dosing, treatment duration, and whether it can slow the decline of movement and other functions, while also monitoring for potential long-term side effects.
It’s important to note that acquiring sulforaphane through food, such as eating more broccoli, is not a proven way to prevent or cure Friedreich ataxia. The powerful findings hinge on a specific, purified form of the compound, which may behave differently in the body compared to dietary sources.
What makes sulforaphane particularly promising is its ability to target multiple aspects of the disease—raising frataxin levels while reducing cellular stress and inflammation. These combined effects could make it a compelling candidate for further research.
Still, laboratory success doesn’t always lead to effective human treatments. The human body processes compounds differently, and improvements observed in lab settings do not always translate into slowed disease progression. Despite this, existing safety data and availability of pure sulforaphane could streamline future development efforts if clinical trials show positive results. The research team is now seeking support to advance toward human testing.
Given that Friedreich ataxia affects a relatively small number of families, raising awareness is almost as crucial as scientific discovery. Increased attention can lead to more funding, greater patient participation, and the clinical studies necessary to determine if a compound derived from broccoli can truly make a difference.
For those interested in nutrition, it’s worth exploring studies on the benefits of beetroot juice, the risks tied to combining dietary supplements with medications, and natural approaches to boosting iron for anemia. Recent research also indicates that vitamin K could reduce heart disease risk by about a third.
Source: Swinburne University of Technology.
